Chondroplasty Market Report 2026

The chondroplasty market size has grown strongly in recent years. It will grow from $14.62 billion in 2025 to $15.44 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increasing incidence of osteoarthritis, rising sports-related joint injuries, expansion of orthopedic surgical infrastructure, growing acceptance of arthroscopic procedures, availability of advanced surgical tools.

The chondroplasty market size is expected to see strong growth in the next few years. It will grow to $19.77 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing aging population with joint disorders, rising preference for minimally invasive orthopedic treatments, expansion of sports medicine services, growing adoption of advanced cartilage repair technologies, increasing investment in orthopedic surgical innovation. Major trends in the forecast period include increasing adoption of minimally invasive cartilage repair procedures, rising use of radiofrequency ablation techniques, growing demand for arthroscopic chondroplasty devices, expansion of outpatient orthopedic surgeries, enhanced focus on joint preservation treatments.

The rising incidence of joint-related disorders is expected to drive growth in the chondroplasty market. Joint disorders are conditions that affect the health and function of joints, often caused by overuse, sudden injury, accidents, or sports-related trauma. Chondroplasty treats these disorders by repairing damaged cartilage within the joint. For example, in February 2025, Arthritis Australia, an Australia-based non-profit organization, estimated that approximately 5.39 million Australians were living with arthritis, representing a 31% increase since 2025. Consequently, the growing prevalence of joint-related disorders is fueling the expansion of the chondroplasty market.

Key companies in the chondroplasty market are developing autologous chondrocyte therapies to improve cartilage repair using the patient’s own cells, which reduces immune rejection and supports natural tissue regeneration. Autologous chondrocytes are cartilage cells harvested from a patient’s non-weight-bearing joint area. For instance, in August 2024, Vericel Corporation, a US-based biopharmaceutical company, received FDA approval and commercialized MACI Arthro (Matrix Autologous Chondrocyte Implantation), a major advancement for treating knee cartilage defects. MACI Arthro enables orthopedic surgeons to perform the procedure through small incisions using specialized instruments, offering a less invasive alternative to traditional methods, improving patient recovery and reducing post-operative complications.

In July 2023, Avanos Medical Inc., a US-based provider of therapies and solutions for pain management and chronic care, acquired Diros Technology Inc. for $60 million. This acquisition strengthens Avanos’ position in RF technology by expanding its portfolio with innovative pain treatment devices. Diros Technology Inc., a Canada-based company, manufactures radiofrequency devices for joint disorders, including knee, cervical, and lumbar pain.

Major companies operating in the chondroplasty market are Johnson & Johnson, Osiris Therapeutics Inc., Medtronic Public Limited Company, Stryker Corporation, B. Braun Melsungen AG, Zimmer Biomet Holdings Inc., Smith & Nephew plc, Arthrex Inc., CONMED Corporation, Organogenesis Holdings Inc., Bioventus LLC, RTI Surgical Holdings Inc., Vericel Corporation, Geistlich Pharma AG, MEDIPOST Co. Ltd., GPC Medical Ltd., Sklar Surgical Instruments, Isto Biologics, NuOrtho Surgical Inc., Medical Devices Business Services Inc.

North America was the largest region in the chondroplasty market in 2025. The regions covered in the chondroplasty market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chondroplasty market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the chondroplasty market by increasing costs of imported arthroscopic instruments, radiofrequency devices, surgical shavers, and specialized orthopedic equipment. Hospitals and orthopedic clinics in North America and Europe are most affected due to reliance on imported surgical technologies, while Asia-Pacific faces cost pressures on equipment sourcing. These tariffs are increasing procedural costs and capital expenditure for healthcare providers. At the same time, they are encouraging local manufacturing of orthopedic devices, regional supplier partnerships, and investment in cost-efficient surgical equipment development.

The chondroplasty market research report is one of a series of new reports that provides chondroplasty market statistics, including chondroplasty industry global market size, regional shares, competitors with a chondroplasty market share, detailed chondroplasty market segments, market trends and opportunities, and any further data you may need to thrive in the chondroplasty industry. This chondroplasty market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chondroplasty is a surgical procedure that repairs and reshapes damaged cartilage within a joint. It is generally performed to relieve pain and improve joint function, particularly in cases of cartilage damage caused by osteoarthritis, traumatic injuries, or other joint disorders.

The main types of chondroplasty include radiofrequency ablation chondroplasty, abrasion chondroplasty, patellar chondroplasty, meniscal repair, tissue removal, and others. Radiofrequency ablation chondroplasty targets minor imperfections in knee cartilage to slow joint deterioration. The procedures are performed on various joint anatomies, including the knee, shoulder, and hip, using instruments such as shavers, radiofrequency devices, and arthroscopes. The primary end users of these treatments are hospitals, orthopedic clinics, academic research institutions, and other healthcare providers.

The chondroplasty market includes revenues earned by entities by providing services such as microfracture surgery, laser-assisted treatments, and autologous chondrocyte transplantation (ACT). The market value includes the value of related goods sold by the service provider or included within the service offering. The chondroplasty market also includes sales of radiofrequency ablation devices and autologous chondrocyte implants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.